‘I Want Everything To Go Faster’: Medidata’s CEO On Pushing The Strategic Accelerator

Appointed CEO 12 months ago, Anthony Costello wasted no time in orchestrating strategic change at Medidata. He talked to In Vivo about the art of the pivot and how to constantly push boundaries.

Anthony Costello Presents At Medidata's NEXT Conference (Medidata)
Key Takeaways
  • Anthony Costello's impatience with inefficiency has driven significant innovations in clinical trial technology. His leadership style is characterized by a startup mindset, the need to push boundaries, and the ability to adapt quickly to change. 
  • Costello has led a major strategic pivot at Medidata, shifting from a product-focused strategy to an experience-focused strategy, which involved reorganizing 35 product lines into three experiences.  
  • Regulators need to work faster to provide crucial guidance on the way companies can use AI in clinical trials, he said. While technology is innovating at a lightning pace, it is being held back by application in regulation. 

In the fast-paced world of clinical trial technology, Anthony Costello stands as an example of how entrepreneurial spirit, impatience with the status quo and a genuine passion for health care...

Costello brought many years of experience and a startup mindset to leading clinical trials platform Medidata Solutions, the company he came into in 2017 and of which he was promoted...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from C-Suite Speaks

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By 

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By 

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By 

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.

More from Innovation

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By 

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By 

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By 

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.